Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results
Phase III Data Could Lead To First Approval
Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.
You may also be interested in...
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.
Certain launch challenges aside, the early commercial metrics and physician feedback look encouraging for Incyte's recently-approved topical JAK Opzelura for eczema.
Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance
US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.